榴莲视频

Zolbetuximab indicated alongside fluoropyrimidine- and platinum-containing chemotherapy

Greater benefit seen with higher dose of tulisokibart at week 50

Each of these specialties average over $500k per year

Knowing what to look for can mean the difference between life and death

Bowel preparation protocols appeared protective in small study

Gastric cancer incidence was lower after adjusting for certain factors in post hoc analyses

Despite problematic dataset, risk/benefit profile not favorable with PD-L1 expression below 1

26% of patients receiving tulisokibart achieved clinical remission vs 1% with placebo

Data since approvals suggest benefits limited to subgroups with PD-L1 expression of at least 1%

Drugmaker none-too-pleased with agency's request for additional studies

Agency advisors put their foot down on shaky science for Ocaliva in primary biliary cholangitis

In trials, guselkumab more than doubled remission rates versus placebo

Agency advisory panel to examine complicated efficacy data and liver safety concerns